肥満：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 11
1.2 List of Figures 20
2 Introduction 24
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 29
3.2 Symptoms 31
4 Epidemiology 32
4.1 Disease Overview 32
4.2 Risk Factors and Comorbidities 33
4.3 Global Trends 39
4.4 Forecast Methodology 55
4.5 Epidemiology Forecast of Overweight (2012-2022) 88
4.6 Epidemiology Forecast of Obesity (2012-2022) 95
4.7 Epidemiology Forecast of Obesity Class I (2012-2022) 102
4.8 Epidemiology Forecast of Obesity Class II (2012-2022) 109
4.9 Epidemiology Forecast of Obesity Class III (2012-2022) 118
4.10 Epidemiology Forecast of Comorbidities among Adults with Overweight/Obesity (2012 and 2022) 126
4.11 Discussion 133
5 Disease Management 136
5.1 Treatment Overview 136
5.2 US 142
5.3 France 147
5.4 Germany 151
5.5 Italy 158
5.6 Spain 163
5.7 UK 165
5.8 Japan 168
5.9 Brazil 171
5.10 Canada 177
6 Competitive Assessment 180
6.1 Overview 180
6.2 Strategic Competitor Assessment 184
6.3 Product Profiles: Drugs 186
6.4 Product Profiles: Medical Devices – Artifical Fulness Devices 219
6.5 Product Profiles: Medical Devices – Endoscopic Surgical Devices 240
6.6 Product Profiles: Medical Devices – Gastric Electrical Stimulation 249
6.7 Product Profiles: Medical Devices – Malabsorption Devices 257
6.8 Product Profiles: Medical Devices – Neuronal Blocking Technology 260
6.9 Product Profiles: Medical Devices – Restrictive Devices 262
7 Opportunity and Unmet Need 286
7.1 Overview 286
7.2 A Drug with Greater Than 10% Average Weight Loss 288
7.3 A Drug with Increased Safety and Tolerability 290
7.4 Reimbursement by Private and Public Payers 292
7.5 Increased Physician Education 295
7.6 Increased Drug-Treatment Rate 297
7.7 Improved Guidelines 299
7.8 Improved Approach to Diagnosis 301
8 Pipeline Assessment 302
8.1 Overview 302
8.2 Clinical Trial Mapping 306
8.3 Clinical Trials by Phase and Trial Status 307
8.4 Promising Drugs in Clinical Development 308
8.5 Artificial Fullness Devices 338
8.6 Promising Deep-Brain Stimulation Devices in Development 342
8.7 Promising Endoscopic Surgical Devices 345
8.8 Promising Malabsorption Devices in Development 349
8.9 Promising Restrictive Devices in Development 351
9 Current and Future Players 358
9.1 Overview 358
9.2 Trends in Corporate Strategy 363
9.3 Company Profiles: Pharmaceutical and Biotech Companies 364
9.4 Company Profiles: Device Companies 383
10 Market Outlook 419
10.1 Global Markets 421
10.2 United States 431
10.3 France 440
10.4 Germany 446
10.5 Italy 453
10.6 Spain 460
10.7 United Kingdom 466
10.8 Japan 473
10.9 Brazil 479
10.10 Canada 486
11 Appendix 492
11.1 Bibliography 492
11.2 Abbreviations 515
11.3 Research Methodology 521
11.4 Forecasting Methodology 522
11.5 Physicians, Specialists, and Payers Included in This Study 530
11.6 About the Authors 532
11.7 About GlobalData 535
11.8 Disclaimer 535